Cofinimmo SA

LSE:0J3X Stock Report

Market Cap: €2.1b

Cofinimmo Past Earnings Performance

Past criteria checks 0/6

Cofinimmo's earnings have been declining at an average annual rate of -13.8%, while the Health Care REITs industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 8.8% per year.

Key information

-13.8%

Earnings growth rate

-17.8%

EPS growth rate

Health Care REITs Industry Growth7.7%
Revenue growth rate8.8%
Return on equity-1.3%
Net Margin-13.3%
Next Earnings Update21 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cofinimmo makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0J3X Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24392-52120
30 Jun 24392-41130
31 Mar 24391-55140
31 Dec 23389-55140
30 Sep 2337949160
30 Jun 23379185150
31 Mar 23373333140
31 Dec 22368483140
30 Sep 22367565160
30 Jun 22357489140
31 Mar 22351382130
31 Dec 21343260120
30 Sep 21328189150
30 Jun 21312155130
31 Mar 21276122180
31 Dec 20293119100
30 Sep 20296170120
30 Jun 20266193220
31 Mar 2029222290
31 Dec 1928520590
30 Sep 19241134240
30 Jun 1927011980
31 Mar 1925910580
31 Dec 1826314680
30 Sep 1826018680
30 Jun 1825817080
31 Mar 1826416680
31 Dec 1726313780
30 Sep 1726712180
30 Jun 1726712880
31 Mar 1727513480
31 Dec 162579790
30 Sep 1625310090
30 Jun 162558290
31 Mar 1624911090
31 Dec 1525510480
30 Sep 152607680
30 Jun 152626680
31 Mar 15264-5980
31 Dec 14259-5380
30 Sep 14270-5180
30 Jun 14274-3980
31 Mar 142763780
31 Dec 132735980

Quality Earnings: 0J3X is currently unprofitable.

Growing Profit Margin: 0J3X is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0J3X is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.

Accelerating Growth: Unable to compare 0J3X's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0J3X is unprofitable, making it difficult to compare its past year earnings growth to the Health Care REITs industry (29.2%).

Return on Equity

High ROE: 0J3X has a negative Return on Equity (-1.3%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:48
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cofinimmo SA is covered by 31 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert Jan VosABN AMRO Bank N.V.
Celine HuynhBarclays
Celine Soo-HuynhBarclays